Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Reduce" from Brokerages

Key Points

• Hims & Hers Health, Inc. has received an average recommendation of "Reduce" from fourteen research firms, with three sell ratings, nine holds, and two buy recommendations.
• The company reported a 72.6% year-over-year revenue increase, although it missed consensus earnings per share estimates for the recent quarter.
• Recent insider trading activity saw CEO Andrew Dudum sell 660,000 shares, reducing his ownership by 22.96%, as insiders sold over $83 million worth of stock in the last three months.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has received an average recommendation of "Reduce" from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $38.9167.

Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Truist Financial reduced their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. UBS Group set a $30.00 price target on shares of Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group restated a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Hims & Hers Health in a report on Saturday, September 27th.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $53.98 on Friday. The company has a market cap of $12.20 billion, a price-to-earnings ratio of 67.48, a PEG ratio of 3.64 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a 50 day simple moving average of $50.86 and a 200 day simple moving average of $48.00. Hims & Hers Health has a one year low of $17.36 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick Harrison Carroll sold 60,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares in the company, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,622,741 shares of company stock worth $83,695,469 over the last three months. 13.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Virtus Advisers LLC bought a new stake in Hims & Hers Health in the second quarter worth about $26,000. Quaker Wealth Management LLC bought a new stake in Hims & Hers Health in the second quarter worth about $29,000. Bessemer Group Inc. raised its position in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares during the period. Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health in the first quarter worth about $30,000. Finally, Hilltop National Bank bought a new stake in Hims & Hers Health in the third quarter worth about $35,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.